Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 15;25(1):67.
doi: 10.1186/s12879-024-10428-7.

Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19

Catharine I Paules #  1 , Jacqueline A Nordwall #  2 , Kathryn Shaw-Saliba  3 , Judith A Aberg  4 , Edward M Gardner  5 , Anna L Goodman  6 , N Kumarasamy  7 , Shikha Vasudeva  8 , David M Vock  2 , Crystal M North  9   10 , Jens Lundgren #  11 , Neil R Aggarwal #  12 ; STRIVE Network and TICO Trial Study Group
Affiliations

Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19

Catharine I Paules et al. BMC Infect Dis. .

Abstract

Background: Low blood absolute lymphocyte count (ALC) may predict severe COVID-19 outcomes. Knowledge gaps remain regarding the relationship of ALC trajectory with clinical outcomes and factors associated with lymphopenia.

Methods: Our post hoc analysis of the Therapeutics for Inpatients with COVID-19 platform trial utilized proportional hazards models to assess relationships between Day (D) 0 lymphopenia (ALC < 0.9 cells/uL), D0 severe lymphopenia (ALC < 0.5 cells/uL) or lymphopenia trajectory between D0 and D5 with mortality and secondary infections, and with sustained recovery using Fine-Gray models. Logistic regression was used to assess relationships between clinical variables and D0 lymphopenia or lymphopenia trajectory.

Results: D0 lymphopenia (1426/2579) and severe lymphopenia (636/2579) were associated with increased mortality (aHR 1.48; 1.08, 2.05, p = 0.016 and aHR 1.60; 1.20, 2.14, p = 0.001) and decreased recovery (aRRR 0.90; 0.82, 0.99, p = 0.033 and aRRR 0.78; 0.70, 0.87, p < 0.001 respectively). Trial participants with persistent D5 lymphopenia had increased mortality, and increased secondary infections, and participants with persistent or new lymphopenia had impaired recovery, as compared to participants with no lymphopenia. Persistent and new lymphopenia were associated with older age, male sex; prior immunosuppression, heart failure, aspirin use, and normal body mass index; biomarkers of organ damage (renal and lung), and ineffective immune response (elevated IL-6 and viral nucleocapsid antigen levels). Similar results were observed with severe lymphopenia.

Conclusions: Lymphopenia was predictive of severe COVID-19 outcomes, particularly when persistent or new during hospitalization. A better understanding of the underlying risk factors for lymphopenia will help illuminate disease pathogenesis and guide management strategies.

Keywords: Lymphocytes; Precision medicine; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This is a secondary analysis of the TICO platform Institutional Review Board approved trial (NCT04501978), registration date August 3, 2020. The protocol and its amendments for all primary data were reviewed by the appropriate overseeing ethics committees for all sites that implemented the protocol Informed consent was obtained from all participants or their representatives for the primary TICO platform studies. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Time to death Kaplan-Meier curves by lymphopenia trajectory groups (A) and severe lymphopenia trajectory groups (B)
Fig. 2
Fig. 2
Biomarker measurements at Days 0, 1, 3, and 5 by lymphopenia trajectory group. Plasma nucleocapsid antigen (Panel A), C-reactive protein (Panel D), interleukin-6 (Panel E), and D-dimer (Panel F) are non-normally distributed and are summarized by geometric means. Anti-nucleocapsid antibody (Panel B) and anti-spike neutralizing antibody (Panel C) are displayed as means on the original scale
See this image and copyright information in PMC

References

    1. Reijnders TDY, Schuurman AR, Verhoeff J, van den Braber M, Douma RA, Faber DR, et al. High-dimensional phenotyping of the peripheral immune response in community-acquired pneumonia. Front Immunol. 2023;14:1260283. - PMC - PubMed
    1. DeMerle KM, Kennedy JN, Chang CH, Delucchi K, Huang DT, Kravitz MS, et al. Identification of a hyperinflammatory sepsis phenotype using protein biomarker and clinical data in the ProCESS randomized trial. Sci Rep. 2024;14(1):6234. - PMC - PubMed
    1. Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol. 2021;19(7):425–41. - PMC - PubMed
    1. Bermejo-Martin JF, Cilloniz C, Mendez R, Almansa R, Gabarrus A, Ceccato A, et al. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. EBioMedicine. 2017;24:231–6. - PMC - PubMed
    1. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–61. - PMC - PubMed

LinkOut - more resources